Parkinson's Disease and Restless Legs Syndrome - Reformulations set to drive near-term growth

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-08-11

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Despite affecting a large number of individuals, there are currently no treatments capable of curing either Parkinson's disease or Restless Legs Syndrome. Although available treatments are effective, numerous unmet needs prevail. Several compounds are in late-stage development and are forecast to achieve sales of $519m for Parkinson's disease and $399m for Restless Legs Syndrome in 2015.


Scope

  • Analysis of patient potential, unmet needs and clinical trial design in Parkinson's disease and Restless Legs Syndrome across the US, EU and Japan
  • Overview of drugs in pre-registration, Phase III, II, I and preclinical development; with analysis of key companies involved in the market
  • Detailed profiles of key compounds in development for Parkinson's disease and Restless Legs Syndrome, with forecasts of drug revenues to 2015
  • Discussion of innovative early stage products and insight from key industry opinion leaders


    • Report Highlights
    Dopamine agonists with alternative delivery systems are expected to drive near-term changes in the Parkinson's disease market. While Schwarz's rotigotine patch holds several advantages over current oral treatments its success looks set to be eclipsed by GSK's once-daily tablet, Requip Modutab, which is forecast to reach peak sales of $543m in 2011.

    The mid-stage pipeline for Parkinson's disease is unimpressive, with a host of potential neuroprotectants failing to demonstrate conclusive benefits in slowing disease progression. The most exciting near-term prospects are likely to come from cell and gene therapy products such as Titan/Schering's Spheramine or Avigen's AV-201.

    The recent approval of the dopamine agonists Requip and Mirapex for Restless Legs Syndrome have provided a viable treatment option. However, unmet needs still exist and treatments, such as XenoPort's XP13512 which offer alternative mechanisms to dopaminergic stimulation may provide greater symptomatic benefit to current treatments.


    Reasons to Purchase

  • Understand unmet needs in the Parkinson's disease and Restless Legs Syndrome market based on key opinion leader comments
  • Benchmark key late-stage Parkinson's disease and Restless Legs Syndrome compounds against current market leaders
  • Assess the global sales forecasts of late-stage pipeline drugs; and examine their clinical and commercial potential

    • Table of Contents

    Other users found this report page using the following search terms: neuroprotection neurodegeneration neurodegenerative parkinsons study parkinsons 60020407 chiesi talampanel drugs istradefylline burden pill 204

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.